An investigation on behalf of investors of Entellus Medical Inc (NASDAQ:ENTL) in connection with the proposed takeover was announced and NASDAQ:ENTL stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 12/14/2017 -- An investigation was announced for investors in shares of Entellus Medical Inc (NASDAQ:ENTL), over whether the acquisition of Entellus Medical Inc. by Stryker Corporation is unfair.
Investors who purchased shares of Entellus Medical Inc (NASDAQ:ENTL) should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm concerns whether certain officers and directors of Entellus Medical Inc breached their fiduciary duties owed to NASDAQ:ENTL investors in connection with the proposed acquisition.
On December 7, 2017, Entellus Medical Inc (NASDAQ:ENTL) announced a merger agreement by which Stryker Corporation (NYSE:SYK) will acquire Entellus Medical Inc in an all cash transaction for $24.00 per share, or an equity value of approximately $662 million.
However, the investigation concerns whether the offer is unfair to Entellus Medical Inc (NASDAQ:ENTL stockholders. More specifically, the investigation concerns whether the Entellus Medical Inc (NASDAQ:ENTL Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Shares of Entellus Medical Inc (NASDAQ:ENTL) closed on December 12, 2017 at $24.25 per share.
Those who are current investors in Entellus Medical Inc (NASDAQ:ENTL) shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com